Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure[5] - The company's SCD therapy targets the upstream source of effector cells and neutralizes effector cells that release cytokines[28] - The SCD conveniently connects with existing continuous kidney renal therapy that is widely available in U S ICUs today[36] Clinical Data and Approvals - QUELIMMUNE is approved by the FDA as a Humanitarian Use Device (HUD) to treat pediatric patients with acute kidney injury and sepsis or septic condition weighing 10 kilograms and requiring kidney replacement therapy[22] - QUELIMMUNE clinical data in pediatric acute kidney injury shows a 77% survival rate at Day 60 compared to 50% with standard of care[42] - In adult AKI studies, 87.5% of pediatric patients had normal kidney function at Day 60[45] Market Opportunity - The total US annual market opportunity for the Adult AKI market is $4.5 billion, which is 50 times the size of the Pediatric AKI market ($100 million)[24] - The adult acute kidney injury population is 50x larger than the pediatric population[18] Financials - As of May 14, 2025, the company has a market capitalization of $13.5 million[69]
SeaStar Medical Holding (ICU) Earnings Call Presentation